News

Drug Discovery and Design

Kimberly Redmond | Equities.com |

German healthcare conglomerate Bayer AG announced on Thursday it will spend at least $1.5 billion to acquire Vividion Therapeutics, a small US biotechnology firm focused on discovering drugs that target previously unknown binding sites to create novel therapies.

Founded in 2013, San Diego-based Vividion is mainly focused on NRF2-mutant cancers and NRF2 activators for inflammatory diseases, like irritable bowel disease.